Session Chair
Prof. Dennis GILLINGHAM
UNIVERSITY OF BASEL, Basel, Switzerland
09:30
Opening Ceremony
Prof. Rui MOREIRA
UNIVERSITY OF LISBON, Lisbon, Portugal
Prof. Dennis GILLINGHAM
UNIVERSITY OF BASEL, Basel, Switzerland
09:40
KL01 - Powerful New Tools for Augmented Medicinal Chemistry
Dr Werngard CZECHTIZKY
ASTRAZENECA, Mölndal, Sweden
Werngard Czechtizky is Head of Medicinal Chemistry for Respiratory, Inflammation and Autoimmunity (RIA) at AstraZeneca in Gothenburg, Sweden. She has a track record of delivery of clinical candidates and lead compounds across several therapeutic areas (CV, Diabetes, Pain, CNS, Inflammation and Respiratory). Werngard has continuously implemented state of the art technologies into Medicinal Chemistry. These include e.g. efficient integration of machine learning methods into drug discovery projects, setup of New Modalities Medicinal Chemistry capabilities, implementation of automated synthesis, purification and analytics facilities and efficient integration of compound synthesis with physchem & eADME profiling to accelerate DMTA cycles. Werngard is part of AZ’s Global Chemistry Council, serves on scientific advisory boards of journals and conferences, and is co-/author of ca 80 publications and patents. She has studied at the Technical University of Graz, Austria, received a PhD from ETH Zürich and a postdoctoral training at Harvard University. Before joining AZ in 2017, she has been Head of Chemistry at Sanofi Frankfurt, Germany.
10:10
OC01 - Design and Synthesis of Novel Benzothiazole-Piperazine Propanamide Derivatives for Multi-Targeted Approach in Alzheimer's Disease Treatment
Winner of the Young Medicinal Chemist Meeting in Turkey
Ms Bengisu TURGUTALP
YEDITEPE UNIVERSITY, New York, Turkey
Dr. Bengisu Turgutalp earned Bachelor of Pharmacy degree in 2015. She accepted her PhD in the field of pharmaceutical chemistry from Yeditepe University Institute of Health Sciences in 2020. She
served as a teaching and research assistant in Yeditepe University Faculty of Pharmacy within the years of 2015-2020. Currently, she is serving as a full-time assistant professor in the same institution.
Since June 2021, as an Erasmus+ scholar, she is conducting her researches in German Center for Neurodegenerative Diseases in Dresden under the supervision of Associate Professor Caghan Kizil.
10:30
OC02 - Design and Synthesis of Dual Inhibitors Of DYRK1A/CLK1 Kinases Involved in Neurodegenerative Diseases
Winner of the Young Medicinal Chemist Meeting in France
Mrs Clementine PESCHETEAU
ICOA, ORLEANS, France
Clementine Pescheteau obtained in 2018 a Chemistry Engineering degree from Chimie ParisTech (ENSCP, Paris, France) and a Master’s degree in Medicinal Chemistry and Molecular Pharmacology from the University Paris Descartes. She did a four-month internship at University of Glasgow in the medicinal chemistry group of Robert Liskamp, where she worked on an efficient and scalable synthesis of new oligonucleotide monomers. Then she had the opportunity to carry out a six-month internship at Sanofi among the Integrated Drug Discovery team in Chilly-Mazarin. She is currently in 3rd year of PhD at the Organic and Analytical Chemistry Institute (ICOA) in Orléans (France), under the supervision of Pr. Sylvain Routier and Dr. Frederic Buron. Her PhD project, supported by an ANR, is focused on the design and synthesis of selective and dual inhibitors of DYRK1A and CLK1 kinases, involved in neurodegenerative pathologies such as Alzheimer’s disease.
10:50
OC03 - Towards the Development of ACSL4 Selective Inhibitors to Prevent Ferroptosis in Neurodegenerative Diseases
Winner of the Young Medicinal Chemist Meeting in Belgium (SRC)
Mr Romain MARTEAU
LOUVAIN DRUG RESEARCH INSTITUTE, Woluwe-Saint-Lambert, Belgium
Romain Marteau obtained his master’s degree in pharmaceutical sciences in 2017 at the Catholic University of Louvain (UCLouvain). In 2018, he was selected as a teaching assistant at UCLouvain and started a Ph.D in the laboratory of Pr. Raphaël Frédérick at the Louvain Drug Research Institute. His topic of interest include biochemical and biophysical protein characterization and drug discovery.
11:10
Networking Break
11:20
OC04 - Small Organic Molecules to Trigger the Activity of NK Cells
Winner of the Young Medicinal Chemist Meeting in Portugal
Dr Pedro PINHEIRO
INSTITUTO SUPERIOR TÉCNICO, Lisboa, Portugal
Pedro Pinheiro is a Biological Engineering graduate from Instituto Superior Técnico (IST) – University of Lisbon, and received his Ph.D. in Chemistry from the same institution in 2020. His current work focuses on the development of small molecule agonists for the natural killer cell activation receptors and their application in cancer immunotherapy. He is currently working as a researcher in Centro de Química Estrutural – IST.
11:40
OC05 - Novel Hdac6-Selective Inhibitor for Glioblastoma Treatment
Winner of the Young Medicinal Chemist Meeting in Croatia
Dr Maja BEUS
INSTITUTE FOR MEDICAL RESEARCH, Durham, United States
Maja Beus successfully defended her PhD thesis in June 2020 in the field of medicinal chemistry at the Faculty of Pharmacy and Biochemistry, University of Zagreb. Her work was based on designing and synthesizing primaquine derivatives as potential anticancer agents. During her PhD, Maja spent 6 months at McGill University testing a novel HDAC6 inhibitor at the Department of Pharmacology and Therapeutics. Additionally, she won the British scholarship Trust scholarship for short-term research (3 months) at the University of Oxford, working on potential kinase inhibitors for the treatment of Alzheimer’s disease. For her work at Oxford, she was awarded the “Voya Kondic Memorial Prize” given by the British Scholarship Trust for the best use of a study visit. Maja is currently employed as a postdoc at the Institute for Medical Research and Occupational Health where she’s working on the development of nanoparticles for the treatment of Parkinson’s disease.
12:00
OC06 - Design and Synthesis of Brain Penetrant P38-Alpha Mitogen-Activated Protein Kinase Inhibitors
Winner of the Young Medicinal Chemist Meeting in Germany (DPhG)
Dr Pierre KOCH
UNIVERSITÄT REGENSBURG, Germany
Pierre Koch studied chemistry at the University of Tübingen (Germany) and received his Ph.D. in Pharmaceutical Chemistry in 2009 under the supervision of Prof. S. Laufer from the same institution. As a postdoctoral fellow, he worked under the direction of Prof. Michael E. Jung at the University of California, Los Angeles (USA) in the Department of Organic Chemistry as well as in the group of Prof. Christa E. Müller at the University of Bonn. In 2013, he was appointed as assistant professor for medicinal chemistry at the University of Tübingen. Since May 2020, he is working as interim chair of the department of Pharmaceutical/Medicinal Chemistry II at the University of Regensburg.
His research interests are on the design of small molecule kinases inhibitors for the treatment of CNS disorders as well in medicinal chemistry/semi-synthesis of biologically active natural products.
Pierre received the Neuroallianz Publication Price (silver) in 2014 and was awarded with the Nachwuchspreis der DPhG-Stiftung (Horst-Böhme-Stiftung) in 2018. Recently, he received the Innovation Award 2021 in Medicinal and Pharmaceutical Chemistry from the division Medicinal Chemistry of the German Chemical Society (GDCh) and the division Pharmaceutical/Medicinal Chemistry of the German Pharmaceutical Society (DPhG).
Flash Poster Presentations (Odd numbers)
12:20
FP01 - Electrophilic Warheads for The Assessment of Tractable Cysteines
Dr Peter ÁBRÁNYI-BALOGH
RESEARCH CENTRE FOR NATURAL SCIENCES, Budapest, Hungary
FP03 - Synthesis and In Vitro Evaluation of Novel G6Pd Inhibitors
Mr Andrea BACCI
UNIVERSITY OF PISA, Pisa, Italy
FP05 - Synthesis, Development and Evaluation of a Therapeutic Peptide Conjugate to Protect Biomaterials from Undesired Immune Attack
Dr Clément BECHTLER
UNIVERSITY OF BASEL, Wuppertal, Germany
FP07 - Inhibition of the Protein-“Rna Interaction of Lin28 and Let-7 with Trisubstituted Pyrrolinones
Ms Lydia BORGELT
MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany
FP09 - Azaaurones as Novel Chemotypes against Mycobacterium Tuberculosis: Sar, Adme Profiling and Photo-Switching Properties
Mr André CAMPANICO
I.MED.ULISBOA - FFULISBOA, Lisboa, Portugal
FP11 - Protac Technology to Investigate Dysregulation of the Ubiquitin-Proteasome System
Ms Carlotta CECCHINI
UNIVERSITY OF GENEVA, Geneva, Switzerland
FP13 - High-Affinity Glycomimetic Ligands for Human Siglec-8
Mr Gabriele CONTI
UNIVERSITY OF BASEL, Basel, Switzerland
FP15 - Synthesis and Biological Evaluation of Novel Variously Substituted 3-Benzyl-Quinolin-2(1H)-Ones as Potent Agonists of the Gpr55 Receptor
Mrs Ceni COSTANZA
UNIVERSITY OF PISA, Empoli, Italy
FP17 - Design and Synthesis of Novel Androgen Receptor Splice Variant-7 Protacs for the Treatment of Castration-Resistant Prostate Cancer
Ms Jenny DESANTIS
UNIVERSITY OF PADUA, Padova, Italy
FP19 - A Novel Covalent Approach for Stabilising 14-3-3ÎŁ Protein-Protein Interactions
Ms Marta FALCICCHIO
UNIVERSITY OF LEICESTER, Leicester, United Kingdom
12:40
End of Morning Session